CONTENTS:
- Investigating the sociodemographic and behavioural factors associated with hepatitis C virus testing amongst people who inject drugs in England, Wales and Northern Ireland: A quantitative cross-sectional analysis. Yuan J.-M., Croxford S., Viviani L., Emanuel E., Phipps E., Desai M., art. 103821.
- Jail-based reentry programming to support continued treatment with medications for opioid use disorder: Qualitative perspectives and experiences among jail staff in Massachusetts. Matsumoto A., Santelices C., Evans E.A., Pivovarova E., Stopka T.J., Ferguson W.J., et al., art. 103823.
- Understanding the longitudinal relationship between substance use and violent victimization among street-based women who exchange sex in Baltimore, Maryland. Schneider K.E., Tomko C., Nestadt D.F., Rouhani S., White R.H., Decker M.R., et al., art. 103824.
- Barriers to engaging people who use drugs in harm reduction services during the COVID-19 pandemic: A mixed methods study of syringe services program perspectives. Austin E.J., Corcorran M.A., Briggs E.S., Frost M.C., Behrends C.N., Juarez A.M., et al., art. 103825.
- Programmatic alcohol advertising, social media and public health: Algorithms, automated challenges to regulation, and the failure of public oversight. Goodwin I., art. 103826.
- Perceptions of hepatitis C treatment and reinfection risk among HIV-positive men who have sex with men and engage in high risk behaviours for hepatitis C transmission: The CEASE qualitative study. Marshall A.D., Martinello M., Treloar C., Matthews G.V., art. 103828.
- Impact of COVID-19 on the characteristics of opioid overdose deaths in Arkansas. Rezaeiahari M., Fairman B.J., art. 103836.
- Identifying barriers and enablers to opt-out hepatitis C virus screening in provincial prisons in Quebec, Canada: A multilevel, multi-theory informed qualitative study with correctional and healthcare professional stakeholders. Ruiz A.S., Fontaine G., Patey A.M., Grimshaw J.M., Presseau J., Cox J., et al., art. 103837.
- Mortality by cause of death during year 1 of the COVID-19 pandemic in a cohort of older adults from Baltimore Maryland who have injected drugs. Feder K.A., Sun J., Rudolph J.E., Cepeda J., Astemborski J., Baker P.A., et al., art. 103842.
- Patient experiences of prescription drug monitoring programs: a qualitative analysis from an Australian pharmaceutical helpline. Haines S., Lam A., Savic M., Carter A., art. 103847.
- "They didn't have any idea what drugs were": Pathways to substance use disorders among ultraorthodox Jewish males. Itzhaki-Braun Y., Gavriel-Fried B., art. 103851.
- Shifts in substance use patterns among a cohort of people who use opioids after delisting of OxyContin in BC, Canada: An interrupted time series study. Karamouzian M., Buxton J.A., Hategeka C., Nosova E., Hayashi K., Milloy M.J., et al., art. 103852.
- Diagnosis and treatment of opioid-related disorders in a South African private sector medical insurance scheme: A cohort study. Tlali M., Scheibe A., Ruffieux Y., Cornell M., Wettstein A.E., Egger M., et al., art. 103853.
- Twenty-year trends in pharmaceutical fentanyl and illicit fentanyl deaths, Australia 2001-2021. Roxburgh A., Nielsen S., art. 103854.
- Much being Written about Us, not much being Written with Us: Examining how alcohol and other drug use by indigenous Australians is portrayed in Australian Government policies and strategies: A discourse analysis. Gentile V., Jobson L., Carter A., Adams K., art. 103855.
- How do patient, pharmacist and medication characteristics and prescription drug monitoring program alerts influence pharmacists' decisions to dispense opioids? A randomised controlled factorial experiment. Picco L., Sanfilippo P., Xia T., Lam T., Nielsen S., art. 103856.
- Child-centred harm reduction. Barrett D., Stoicescu C., Thumath M., Maynard E., Turner R., Shirley-Beavan S., et al., art. 103857.
- Exploring the experiences of alcohol service use among LGBTQ+ people in Scotland: A qualitative study. Dimova E.D., O'Brien R., Elliott L., Frankis J., Emslie C., art. 103859.
- Evidence-based policymaking: Lessons from the Chilean Substance Use Treatment Policy. Mateo Pinones M., Gonzalez-Santa Cruz A., Portilla Huidobro R., Castillo-Carniglia A., art. 103860.
- Becoming a nitrous oxide user on social media: Learning to maximise pleasures and minimise harms. MacLean S.J., Riddell O., Herold M.D., Frank V.A., art. 103861.
- Construction of group norms in a radical acceptance online forum for heavy alcohol users: A corpus-based discourse analysis. Lustig A., Brookes G., art. 103862.
- The association between MPOWER tobacco control policies and adolescent smoking across 36 countries: An ecological study over time (2006-2014). de Looze M.E., Henking C., Torsheim T., Currie D.B., Weber M.W., Aleman-Diaz A.Y., art. 103871.
- Interventions to prevent HIV and Hepatitis C among people who inject drugs: Latest evidence of effectiveness from a systematic review (2011 to 2020). Palmateer N., Hamill V., Bergenstrom A., Bloomfield H., Gordon L., Stone J., et al., art. 103872.

Special section on UK Drug Strategy:
- Introduction to special section on UK drug strategy [Editorial]. Reuter P., art. 103848.
- Words matter: A commentary on the new UK drug strategy. Ritter A., art. 103846.
- New prospects for harm reduction in the UK? A commentary on the new UK drug strategy. Stevens A., art. 103844.
- 'Breaking supply chains'. A commentary on the new UK Drug Strategy. Bacon M., Spicer J., art. 103843.
- IJDP editorial from harm to hope - A 10-year drugs plan to cut crime and save lives. HM Government 2021. Finch E., art. 103840.
- From harm to hope or is it from harmful to hopeless? Farrell M., art. 103845.
- Encouraging a 'generational shift' in the UKs relationship with drugs. A commentary on the new UK drug strategy. What can be achieved with drug prevention? Sumnall H.R., art. 103841.